Streptococcus pneumoniae: Serotype distribution, antimicrobial susceptibility, risk factors and mortality in Galicia over a two year-period;Streptococcus pneumoniae: distribución de serotipos, sensibilidad antibiótica, factores de riesgo y mortalidad en Galicia en un periodo de 2 años

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 33, Issue 9, 2015, Pages 579-584

  Méndez Lage, Susana ^a   Losada Castillo, Isabel ^b   Agulla Budiño, Andrés ^a  

^a Servicio de Microbiologia   (Spain)

^b Servicio de Epidemioloxía   (Spain)

Author keywords

Invasive pneumococcal disease; Serotypes; Streptococcus pneumonia

Indexed keywords

CEFOTAXIME; ERYTHROMYCIN; LEVOFLOXACIN; PENICILLIN DERIVATIVE; VANCOMYCIN; 13-VALENT PNEUMOCOCCAL VACCINE; ANTIINFECTIVE AGENT; PNEUMOCOCCUS VACCINE; VACCINE;

ANTIBIOTIC SENSITIVITY; ANTIGEN ANTIBODY REACTION; ARTICLE; BACTERIAL STRAIN; CHRONIC RESPIRATORY TRACT DISEASE; DIABETES MELLITUS; FATALITY; HEART DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE DEFICIENCY; KIDNEY; KIDNEY DISEASE; LIVER; LIVER DISEASE; MAJOR CLINICAL STUDY; MORTALITY; RISK FACTOR; SEROTYPE; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; ADOLESCENT; ADULT; AGED; CHILD; CLASSIFICATION; COMORBIDITY; CROSS INFECTION; DRUG EFFECTS; FEMALE; INFANT; ISOLATION AND PURIFICATION; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; PNEUMOCOCCAL INFECTIONS; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SPAIN; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; COMORBIDITY; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RETROSPECTIVE STUDIES; RISK FACTORS; SEROTYPING; SPAIN; STREPTOCOCCUS PNEUMONIAE; SURVIVAL RATE; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 84952978081     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2015.01.010     Document Type: Article

References (30)

1. D.M. Musher Streptococcus pneumonia G.L. Mandell, J.E. Bennett, R. Dolin, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases 7th edition 2010 Churchill, Livingstone, Elsevier
2. Centers for Disease Control and Prevention Active Bacterial Core Surveillance Report, Emerging Infections Program Network Streptococcus pneumoniae 2010
3. J.J. Picazo, F. González-Romo, A. García-Rojas, E. Peréz-Trallero, P. Gil-Gregorio, R. de la Cámara, and et al. Consenso sobre la vacunación anti-neumocócica en el adulto con patología de base Rev Esp Quimioter. 26 2013 232 252
4. M.T. Pérez-Rodríguez, B. Sopeña, S. Méndez-Lage, M. Casares, L.A. de, L. Constenla, A. Argibay, and et al. Influencia de la edad en la enfermedad neumocócica invasiva y en la resistencia a antimicrobianos Med Clin (Barc). 143 2014 287 292
5. W.P. Hausdorff, D.R. Feikin, and K.P. Klugman Epidemiological differences among pneumococcal serotypes Lancet Infect Dis. 5 2005 83 93
6. W.P. Hausdorff, H. Siber, and P.R. Pardiso Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children Lancet. 357 2001 950 952
7. Z.B. Harboe, T.L. Benfield, P. Valentiner-Branth, T. Hjuler, L. Lambertsen, M. Kaltoft, and et al. Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades Clin Infect Dis. 50 2010 329 337
8. M. Luján, J. Burgos, M. Gallego, V. Falcó, G. Bermudo, A. Planes, and et al. Effects of immunocompromise and comorbidities on pneumococcal serotypes causing invasive respiratory infection in adults: Implications for vaccine strategies Clin Infect Dis. 57 2013 1722 1730
9. M.A.G. Rodríguez, A.V. González, M.A.O. Gavín, F.M. Martínez, N.G. Marín, B.R. Blázquez, and et al. Invasive pneumococcal disease: Association between serotype, clinical presentation and lethality Vaccine. 29 2011 5740 5746
10. A.J. Van Hoek, N. Andrews, P.A. Waight, J. Stowe, P. Gates, R. George, and et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England J Infect. 65 2012 17 24
11. G.L. Plosker 13-valent pneumococcal conjugate vaccine: A review of its use in infants, children, and adolescents Paediatr Drugs 15 2013 403 423
12. Dirección de Innovación e Xestión da Saúde Publica, Dirección de Asistencia Sanitaria. Vacunación frente al neumococo. Estudio piloto. Instrucción [monografía de internet]. Santiago de Compostela: Dirección de Innovación e Xestión da Saúde Publica, Dirección de Asistencia Sanitaria. Consellería de Sanidade; 2010 [consultado 14 Nov 2013]. Disponible en: http://www.sergas.es/cas/DocumentacionTecnica/docs/SaudePublica/vacunas/instruccion%20neumococo-castellano.pdf
13. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Twenty-Fourth Informational Supplement. CLSI document M100-S24. 2014.
14. H.C. Slotveb, M. Kaltoft, I.C. Skovsted, M.B. Kerrn, and F. Espersen Simple, rapid latex agglutination test for serotyping of pneumococci (Pneumotest-Latex) J Clin Microbiol. 42 2004 2518 2522
15. R. Austrian The quellung reaction, a neglected microbiologic technique Mt Sinai J Med. 43 1976 699 709
16. R. Dagan, R. Melamed, M. Muallem, L. Piglansky, D. Greenberg, O. Abramson, and et al. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine J Infect Dis. 174 1996 1271 1278
17. C.G. Whitney, M.M. Farley, J. Hadler, L.H. Harrison, N.M. Bennett, R. Lynfield, and et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine N Engl J Med. 348 2003 1737 1746
18. C. Ardanuy, F. Tubau, R. Pallares, L. Calatayud, M.A. Domínguez, D. Rolo, and et al. Epidemiology of invasive pneumococcal disease among adult patients in Barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997-2007 Clin Infect Dis. 48 2009 57 64
19. C. Ardanuy, J.M. Marimón, L. Calatayud, M. Giménez, M. Alonso, I. Grau, and et al. Epidemiology of invasive pneumococcal disease in older people in Spain (2007-2009): Implications for future vaccination strategies PLoS ONE 7 2012 e43619
20. S.S. Richter, K.P. Heilmann, C.L. Dohrn, F. Riahi, D.J. Diekema, and G.V. Doern Pneumococcal serotypes before and after Introduction of Conjugate Vaccines, United States, 1999-2011 Emerg Infect Dis. 19 2013 1074 1083
21. W.H.B. Demczuk, I. Martin, A. Griffith, B. Lefebvre, A. McGeer, M. Lovgren, and et al. Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012 Can J Microbiol. 59 2013 778 788
22. D. Cooper, X. Yu, M. Sidhu, M.H. Nahm, P. Fernsten, and K.U. Jansen The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A Vaccine. 29 2011 7207 7211
23. J. Liñares, C. Ardanuy, R. Pallares, and A. Fenoll Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period Clin Microbiol Infect. 16 2010 402 410
24. C.L. Trotter, P. Waight, N.J. Andrews, M. Slack, A. Efstratiou, R. George, and et al. Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: England and Wales, 1996-2006 J Infect. 60 2010 200 208
25. Cercenado E, Cantón R, editores. Detección fenotípica de mecanismos de resistencia en grampositivos. [monografía de internet]. 2011. Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica; 2011 [consultado 14 Nov 2013]. Disponible en: http://www.seimc.org/contenidos/documentoscientificos/procedimientosmicrobiologia/seimc-procedimientomicrobiologia39.pdf
26. M.C. Green, E.O. Mason, S.L. Kaplan, L.B. Lamberth, S.H. Stovall, L.B. Givner, and et al. Increase in prevalence of Streptococcus pneumoniae serotype 6C at eight Children's Hospitals in the United States from 1993 to 2009 J Clin Microbiol. 49 2011 2097 21011
27. D. Rolo, A. Fenoll, C. Ardanuy, L. Calatayud, M. Cubero, A.G. de la Campa, and et al. Trends of invasive serotype 6C pneumococci in Spain: Emergence of a new lineage J Antimicrob Chemother. 66 2011 1712 1718
28. C. Rock, C. Sadlier, J. Fitzgerald, M. Kelleher, C. Dowling, S. Kelly, and et al. Epidemiology of invasive pneumococcal disease and vaccine provision in a tertiary referral center Europ J Clin Microbiol Infect Dis. 32 2013 1135 1141
29. D.M. Weinberger, Z.B. Harboe, E.A.M. Sanders, M. Ndiritu, K.P. Klugman, S. Rückinger, and et al. Association of serotype with risk of death due to pneumococcal pneumonia: A meta-analysis Clin Infect Dis. 51 2010 692 699
30. M.W. Pletz, T. Welte, and K.P. Klugman The paradox in pneumococcal serotypes: Highly invasive does not mean highly lethal Eur Respir J. 36 2010 712 713